

| To                   | Distributed to:  | Intended action:   |
|----------------------|--|--|
| HSC Board            | Chief Executive<br>Director of Commissioning<br>Director of Integrated Care<br>Assistant Director of Pharmacy and Medicines Management<br>Assistant Director General Medical Services  | For information and onward cascade to relevant staff involved in prescribing, supply or administration arrangements for specialist medicines |
| Public Health Agency | Director of Public Health/Medical Director<br>Director of Nursing and Allied Health Professionals  | For information and onward cascade to relevant staff involved in prescribing, supply or administration arrangements for specialist medicines |
| HSC Trusts           | Chief Executives<br>Medical Directors: for cascade to relevant staff<br>Directors of Acute Services / Clinical Services<br>Directors of Nursing: for cascade to relevant staff<br>Chair of Drug & Therapeutics Committee<br>Directors of Pharmaceutical Services/Head of Pharmacy and Medicines Management<br>Interface Pharmacists Specialist Medicines | For information and onward cascade to relevant staff involved in prescribing, supply or administration arrangements for specialist medicines |
| Other                | Chief Executive, Regulation & Quality Improvement Authority<br>Hospices<br>LMC Chair<br>APAC Chair<br>PCCNI Chair<br>PSNI Chief Executive<br>GPCNI Chair<br>UCA Chair  | For information  |

7<sup>TH</sup> June 2017

Dear colleague

## **Prescribing and supply arrangements for specialist medicines in NI: Update to the Red Amber list (June 2017)**

### **Section 1. Changes to the Red Amber list.**

The Regional Group on Specialist Medicines have agreed the following changes to the Red Amber List:

| <b>Drug</b>                    | <b>Adjudicated indication</b>  | <b>Status*</b> |
|--------------------------------|--|----------------|
| Alectinib (Alecensa®)          | Systemic Anti-Cancer Therapy   | Red            |
| Arsenic (Trisenox®)            | Systemic Anti-Cancer Therapy   | Red            |
| Blinatumomab (Blincyto®)       | Systemic Anti-Cancer Therapy   | Red            |
| Daclizumab (Zinbryta®)         | Multiple sclerosis   | Red            |
| Etelcalcetide (Parsabiv®)      | Treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on haemodialysis. | Red            |
| Everolimus (Votubia®)          | Manifestations of tuberous sclerosis complex   | Red            |
| Follitropin delta (Rekovelle®) | Female infertility   | Red            |
| Immunoglobulin (Cuvitru®)      | Specialist Immunoglobulins   | Red            |

|   |   |                    |
|---|---|--------------------|
| Irinotecan  | Systemic Anti-Cancer Therapy                                | Red                |
| Ixazomib (Ninlaro®)                               | Systemic Anti-Cancer Therapy                                | Red                |
| Migalastat (Galfold®)                             | Fabry disease ( $\alpha$ -galactosidase A deficiency)       | Red                |
| Palbociclib (Ibrance®)                            | Systemic Anti-Cancer Therapy                                | Red                |
| Paritaprevir + ritonavir + ombitasvir (Viekirax®) | Hepatitis C with HIV infection                              | Red                |
| Reslizumab (Cinqaero®)                            | Eosinophilic asthma   | Red                |
| Tedizolid (Sivextro®)                             | Antimicrobial   | Red                |
| Venetoclax (Venclyxto®)                           | Systemic Anti-Cancer Therapy                                | Red                |
| Clonidine   | ADHD and other behavioural and neurodevelopmental disorders | Amber <sup>1</sup> |
| Glycerol phenylbutyrate (Ravicti®)                | Urea cycle disorders  | Amber <sup>2</sup> |
| Liothyronine                                      | Management of thyroid disorders                             | Amber              |

**\* This advice does not take into account any commissioning decisions associated with the potential use of a medicine in either primary or secondary care.**

**<sup>1</sup> A regional shared care guideline is not required to be developed. Consultants should ensure that GPs are provided with sufficient information to enable them to safely prescribe these medicines for each individual patient.**

**<sup>2</sup> A GP information sheet will be developed to support shared care arrangements.**

A revised edition of the Red Amber List has been published to reflect these changes and can be accessed at the Interface Pharmacists Network Specialist Medicines website [www.ipnsm.hscni.net](http://www.ipnsm.hscni.net)

## **Section 2. Endorsement of Regional Shared Care Guidelines and GP Information Sheets for Amber Medicines.**

Shared-care arrangements for specialist medicines enable GPs to prescribe amber list specialist medicines by providing the GP with the necessary information and support to do so safely and effectively.

The Group have endorsed Guidelines for the following medicines to support effective shared-care arrangements, and provide consistency in approach. Implementation should now be brought forward at local level.

| <b>Drug</b>   | <b>Indication(s)</b>            | <b>Link to Guidance</b> |
|---|---------------------------------|-------------------------|
| Azathioprine (adult)  | Non-transplant indications      | <a href="#">Link</a>    |
| Azathioprine (paediatric & adolescent)                        | Non-transplant indications      | <a href="#">Link</a>    |
| Ciclosporin   | Non-transplant indications      | <a href="#">Link</a>    |
| Colistimethate Inhaled (Colomycin®)                           | Pseudomonas lung infection      | <a href="#">Link</a>    |
| Cyclophosphamide  | Multiple indications            | <a href="#">Link</a>    |
| Demeclocycline  | SIADH                           | <a href="#">Link</a>    |
| Dronedarone   | Cardiology                      | <a href="#">Link</a>    |
| Hydroxycarbamide  | Multiple indications            | <a href="#">Link</a>    |
| Hydroxychloroquine  | Dermatology / Rheumatology      | <a href="#">Link</a>    |
| Leflunomide   | Multiple indications            | <a href="#">Link</a>    |
| Mercaptopurine  | Gastroenterology                | <a href="#">Link</a>    |
| Methotrexate oral (adult)                                     | Multiple indications            | <a href="#">Link</a>    |
| Methotrexate oral (paediatric & adolescent)                   | Multiple indications            | <a href="#">Link</a>    |
| Methotrexate subcutaneous injection (adult)                   | Multiple indications            | <a href="#">Link</a>    |
| Methotrexate subcutaneous injection (paediatric & adolescent) | Multiple indications            | <a href="#">Link</a>    |
| Mycophenolate mofetil   | Non-transplant indications      | <a href="#">Link</a>    |
| Penicillamine   | Rheumatology                    | <a href="#">Link</a>    |
| Sodium aurothiomalate injection                               | Rheumatology / Dermatology      | <a href="#">Link</a>    |
| Sulfasalazine   | Gastroenterology / Rheumatology | <a href="#">Link</a>    |
| Tadalafil   | Pulmonary arterial hypertension | <a href="#">Link</a>    |

## **Background**

The Regional Group on Specialist Medicines, a subcommittee of the HSCB medicine management forum, provides advice to prescribers regarding the prescribing and supply of specialist medicines in Northern Ireland using a red and amber 'traffic light' system.

Guidance in the Red / Amber List serves ONLY to define where clinical and prescribing responsibility for the listed medicines should lie in terms of governance and safety.

- Inclusion in this list does NOT imply the drug has been accepted for use via Managed Entry, does NOT imply endorsement of use, and does NOT take account of the cost implications of use of a particular medicine.
- Prescribers should use this list in conjunction with guidance on the [Managed entry process for medicines](#), and the [NI formulary](#).

**Red List Drugs:** prescribing responsibility should remain with the consultant or specialist clinician and the supply organised via the hospital pharmacy.

**Amber List Drugs:** prescribing responsibility should be transferred from secondary to primary care with the agreement of the patient's GP and when shared care arrangements have been established.


Implementation of the red/amber list is facilitated by The Interface Pharmacist Network Specialist Medicines (IPNSM), and helps to ensure:

- Safer systems, with the responsibility for prescribing specialised medicines lying with the most appropriate practitioner.
- Better communication between primary and secondary care leading to better working relationships and enhanced patient care.
- Consistency in approach across Northern Ireland.

On behalf of the Regional Group on Specialist medicines we would request that when you receive this, you cascade it on as indicated above. If you are prescribing specialist medicines, the Red Amber list will be relevant to you. To view the [Red Amber list](#), Regional Shared Care Guidelines, and the contact details of the IPNSM visit [www.ipnsm.hscni.net](http://www.ipnsm.hscni.net).

Thank you for your co-operation in this matter

Yours sincerely



Ms Lynn Keenan  
Regional Group on Specialist Medicines